Free EHR, EHR and Healthcare IT Newsletter Want to receive the latest updates on EHR, EMR and Healthcare IT news sent straight to your email? Get all the latest EHR News for FREE!

Prognos, Healthcare AI Company, Raises $20.5 Million Towards Predicting Disease the Earliest

Cigna, GIS Strategic Ventures, Hermed, Hikma Ventures, Maywic, Merck GHI Fund, and Safeguard Scientifics bet on Prognos to revolutionize healthcare by driving earlier decisions that improve patient health and lower costs

NEW YORK, November 30, 2017 — Prognoswww.prognos.ai, an innovator in applying artificial intelligence (AI) to clinical lab diagnostics, has completed a $20.5 million Series C round of financing, bringing the company’s total funding to $42 million. The investors include CignaGIS Strategic Ventures (the venture capital arm of the Guardian Life Insurance Company), Hermed,  Hikma VenturesMaywicMerck Global Health Innovation Fund (GHI), and Safeguard Scientifics. The support validates Prognos’ leadership position in the market as the only healthcare AI company capable of delivering forward-looking and real-time insights based on laboratory and diagnostics records.

Building on Prognos’ seven-year foundation, the Series C financing will help the company meet highly targeted growth goals in the Life Sciences and Payer markets. Prognos’ solutions enable earlier identification of patients who can benefit from enhanced treatment decision-making, risk management, and quality improvement. The company is currently helping 25 Life Sciences brands to find and convert appropriate patients while building a footprint in the payer market.

“For Prognos, Series C is a focused and disciplined effort to build on our success to scale the business as we pursue our mission of predicting disease earlier to drive better outcomes for patients,” said Sundeep Bhan, Cofounder and CEO of Prognos. “We view this round as a vote of confidence from the healthcare giants and global investment firms that understand the space well and believe that Prognos can continue to lead in providing early insights to deliver better patient care and lower costs.”

The new funds will go toward expanding Prognos’ AI capabilities, new markets, and sales and marketing efforts. To date, Prognos has built the largest lab connectivity network in the U.S., processed and analyzed over 13 billion lab records for more than 180 million patients, and developed 1,000+ proprietary machine learning-enabled algorithms across 50 conditions, such as diabetes, asthma, and non-small cell lung cancer, for the lab data management and analysis. Within the last year, Prognos has also bolstered its leadership team with the additions of Chief Operating Officer Lisa Kerber, Chief Commercial Officer Stephen Silvestro and Chief Data Scientist Fernando Schwartz, Ph.D.

“The Life Sciences industry is increasingly structured around biomarkers and smaller populations where early diagnosis and treatment are key for improving outcomes,” said Joe Volpe, Managing Director, Merck GHI Fund. “Healthcare AI and the right kind of big data, such as lab and diagnostics data driving clinical decision-making, can enable us to predict which patients will benefit from a particular therapy. This round continues our investment into Prognos, the AI company that has demonstrated its capability to transform how the Life Sciences industry does business, now and in the future.”

Global health service company Cigna has been working with Prognos to use lab data and analytics to improve health engagement among its Individual and Family Plan customers.

“AI is a game changer in healthcare risk management,” said Craig Cimini, VP Strategy and Business Development at Cigna. “We have seen Prognos’ capabilities first-hand and believe health plans will greatly benefit from integrating real-time lab and diagnostics data intelligence to refine their approaches to risk adjustment, clinical quality, and care management.”

About Prognos

Prognos is a healthcare AI company focused on predicting disease to drive decisions earlier in healthcare in collaboration with payers, Life Sciences and diagnostics companies. The Prognos Registry is the largest source of clinical diagnostics information in 50 disease areas, with over 13B medical records for 180M patients. Prognos has 1000 extensive proprietary and learning clinical algorithms to enable earlier patient identification for enhanced treatment decision-making, risk management and quality improvement. The company is supported by a $42M investment from Safeguard Scientifics, Inc. (NYSE: SFE), Merck Global Health Innovation Fund (GHIF), Cigna (CI), GIS Strategic Ventures, Hikma Ventures, Hermed Capital, and Maywic Select Investments. For more information, visit www.prognos.ai.

November 30, 2017 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.

Exostar Obtains $5 Million Investment for their Growing Healthcare Business

HERNDON, VA, October 7, 2014Exostar, an innovative information technology company offering cloud-based solutions that enable secure, cost-effective business-to-business collaboration, today announced a $5.0 million investment to enable them to accelerate the growth and expansion of their healthcare and life science business.

Exostar’s cloud-based authentication identity hub for the healthcare industry, Secure Access Manager (SAM), connects customers with other organizations securely across large communities of users. The investment, made by the Merck Global Health Innovation Fund, will help Exostar maintain its rapid growth in these markets and expand into related verticals.

The healthcare industry continues to become more reliant on secure connections, not only to ensure organizations meet all compliance issues, but to support critical digital health applications such as ePrescribing, Health Information Exchange (HIE), and clinical collaboration.  Exostar leverages over a decade of experience helping companies access, utilize and share business-critical information and applications through an easy-to-use, secure Software as a Service (SaaS) model.

“Exostar has successfully expanded from its Aerospace & Defense heritage into other vertical markets that have similar requirements for secure collaboration, complex supply chain needs or identity management to support their core business processes,” said Richard Addi, Exostar’s CEO.  “Our solution is an ideal fit for the healthcare and life science community that needs to set up connections with partners and their applications quickly and securely.  Exostar helps its customers connect with thousands of partners in their ecosystem without compromising network security or intellectual property.”

Originally established by some of the largest companies in the pharmaceutical and life sciences industry, the Exostar life sciences identity hub today includes more than 600 life science focused companies, government agencies and universities supporting the collaboration initiatives of thousands of individuals.

“Exostar’s secure cloud-based access and existing user base delivers a strong complement to the current and future needs of the data-driven healthcare industry,” said Joe Volpe of Merck’s Global Health Innovation Fund.

About Exostar

Exostar powers secure business-to-business information sharing, collaboration and business process integration throughout the value chain.  Exostar supports the complex trading needs of many of the world’s largest companies in aerospace and defense, life sciences, and other industries.  Exostar’s cloud-based identity assurance products and business applications reduce risk, improve agility and strengthen trading partner relationships and profitability for over 100,000 companies in 150 countries worldwide.  The Exostar community includes market leaders such as AstraZeneca, BAE Systems, Bell Helicopter, The Boeing Company, Computer Sciences Corporation, Lockheed Martin Corp., Merck, Newport News Shipbuilding, Northrop Grumman, Raytheon Co. and Rolls-Royce.  For more information, please visit www.exostar.com.

About Merck Global Health Innovation Fund, LLC

Merck Global Health Innovation Fund, LLC (GHIF) invests in emerging companies that deliver breakthrough health care solutions, which advance Merck’s mission to discover, develop and provide innovative products and services that save and improve lives. For more information, visit http://www.merck.com/ghi.

October 7, 2014 I Written By

John Lynn is the Founder of the HealthcareScene.com blog network which currently consists of 10 blogs containing over 8000 articles with John having written over 4000 of the articles himself. These EMR and Healthcare IT related articles have been viewed over 16 million times. John also manages Healthcare IT Central and Healthcare IT Today, the leading career Health IT job board and blog. John is co-founder of InfluentialNetworks.com and Physia.com. John is highly involved in social media, and in addition to his blogs can also be found on Twitter: @techguy and @ehrandhit and LinkedIn.